Dr. Martens (LON:DOCS) Insider Ije Nwokori Buys 179 Shares of Stock

Dr. Martens plc (LON:DOCS) insider Ije Nwokori bought 179 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The stock was purchased at an average price of GBX 84 per share, for a total transaction of £150.36.

Ije Nwokori also recently made the following trade(s):

• On Thursday, June 25th, Ije Nwokori purchased 118,516 shares of Dr. Martens stock. The stock was purchased at an average price of GBX 72 per share, for a total transaction of £85,331.52.
• On Thursday, June 11th, Ije Nwokori acquired 202 shares of Dr. Martens stock. The shares were acquired at an average price of GBX 74 per share, with a total value of £149.48.
• On Friday, June 12th, Ije Nwokori purchased 112,500 shares of Dr. Martens stock. The shares were bought at an average price of GBX 76 per share, with a total value of £85,500.

Dr. Martens Stock Performance

DOCS stock traded up GBX 0.60 during midday trading on Thursday, hitting GBX 88.80. The company’s stock had a trading volume of 18,918,002 shares, compared to its average volume of 7,381,275. The stock’s 50-day moving average price is GBX 74.52 and its 200 day moving average price is GBX 69.18. The company has a quick ratio of 1.13, a current ratio of 2.61 and a debt-to-equity ratio of 108.85. Dr. Martens plc has a 1 year low of GBX 59.15 and a 1 year high of GBX 100.87. The stock has a market cap of £849.92 million, a price-to-earnings ratio of 37.00, a PEG ratio of 6.40 and a beta of 0.26.

Dr. Martens (LON:DOCS) last released its earnings results on Tuesday, May 19th. The company reported GBX 4.20 earnings per share (EPS) for the quarter. Dr. Martens had a return on equity of 6.89% and a net margin of 3.11%.The business had revenue of £764.90 million during the quarter. On average, equities analysts forecast that Dr. Martens plc will post 2.5809394 EPS for the current year.

Analysts Set New Price Targets

DOCS has been the subject of a number of research analyst reports. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a GBX 100 price target on shares of Dr. Martens in a report on Tuesday, June 2nd. Berenberg Bank cut their price target on Dr. Martens from GBX 114 to GBX 110 and set a “buy” rating for the company in a research note on Tuesday, May 19th. Two analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of GBX 105.

Dr. Martens Company Profile

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.